KPRX: Kiora Pharmaceuticals Inc. Company Short-Term Debt

Symbol and logo of brand kiorapharma.com (KPRX)

Kiora Pharmaceuticals (KPRX) is implementing green chemistry principles and optimizing energy consumption across its laboratories. Anticipation of interim test results for new drugs serves as the primary driver, while development risks are already priced in at 0.00. The business relies on intellectual property protection and orphan drug status to combat rare visual pathologies. The current market quotes visualized below allow for an assessment of Kiora Pharmaceuticals (KPRX) stock dynamics.

KPRX (kiorapharma.com) Company Short-Term Debts history from 07/04/2022 to 10/30/2026

Analytical breakdowns and data insights for company Kiora Pharmaceuticals Inc. (KPRX)

- current quotes and average value forecast:
Price Chart Kiora Pharma|KPRX - Fair Value Consensus
- market capitalization information:
Market Value Kiora Pharmaceuticals, Inc.|KPRX - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Book Value per Share Kiora Pharmaceuticals|KPRX - Book Capitalization|Market Cap to Net Assets Ratio kiorapharma.com|KPRX - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital Kiora Pharmaceuticals|KPRX - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Kiora Pharma|KPRX - Company Cumulative Debt|Debts to Book Capitalization Kiora Pharmaceuticals, Inc.|KPRX - Long-Term Debt|Company Short-Term Debt Kiora Pharmaceuticals|Quick Liquidity kiorapharma.com
- net income and valuation multiples indicators:
KPRX - Net Profit
Basic company analysis:kiorapharma.com (KPRX)
Manufactured products of Kiora Pharmaceuticals

This indicator measures total liabilities with a maturity of up to one year, reflecting the current liquidity burden and the risk of cash flow gaps when assessing business value. Analyzing short-term balance sheet liabilities allows investors to monitor the financial stability of Kiora Pharmaceuticals (KPRX), whose resources are focused on costly R&D in nano-ophthalmology and the development of KIO-301 photoswitches.

Main competitors

ALC - Company Short-Term Debt|Company Short-Term Loans and Borrowings BLCO (Bausch & Lomb)|Glaukos Corp. (GKOS) - Company Short-Term Debt|Company Current Liabilities Apellis Corp|BLTE (Belite Bio Inc) - Company Short-Term Debts|Company Short-Term Debts ocutx.com|Company Current Liabilities HROW (Harrow)|VRDN (Viridian Therapeutics Inc) - Company Short-Term Loans and Borrowings|Company Short-Term Debts LENZ (LENZ Pharma)|Oculis (OCS) - Short-Term Debt|EYPT: Company Current Liabilities|Short-Term Debt kodiak.com|ALDX: Company Short-Term Debts|Short-Term Debt KALA BIO (KALA)|Company Short-Term Debt Opus Genetics, Inc.|OKYO Pharma Inc (OKYO) - Short-Term Debt Volume|Company Short-Term Debt Adverum Biotechnologies (ADVM)|Company Short-Term Debts outlooktherapeutics.com (OTLK)|Company Short-Term Debts CLSD (Clearside Biomedical, Inc.)|Short-Term Debt Volume NovaBay Pharmaceuticals Inc. (NBY)|ALIM - Company Short-Term Debt|Short-Term Debt Eyenovia, Inc.|Guardion Health Science (GHSI) - Company Short-Term Debt|ocuphire.com - Company Short-Term Loans and Borrowings|OPT (Opthea) - Company Short-Term Debts